1[1]Jeanine DA. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction [ J ]. Trends Cardiovasc Med, 2002, 12:97-101.
2[2]Nagase H. Activation mechanisms of matrix metalloproteinases[J]. Biol Chem, 1997, 378:151 -160.
3[3]Elise Lambert, Emilie Dassé, Bernard Haye, et al. TIMPs as multifacial proteins[J]. Crit Rev Onco Hemato, 2004, 49(3):187 - 198.
4[4]Gan X, Wong B, Wright SD, et al. Production of matrix metalloproteinase- 9 in CaCO -2 cells in response to inflammatory stimuli[J]. J Interferon Cytokine Res, 2001, 21(2) :93 -98.
5[5]Kouwenhoven M, Carlstrom C, Ozenci V, et al. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke[J]. J Clin Immunol, 2001,21(5) :365 -375.
6[6]Wolfgang Eberhardt, Andrea Huwiler, Karl - Friedrich Beck, et al. Amplification of IL - 1 β - induced matrix metalloproteinase- 9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF - κB and activating protein - 1 involves activation of the mitogen - activated protein kinase pathways[ J]. J Immunol, 2000, 165(10) :5788- 5797.
7[7]Bond M, Chase AJ, Baker AH, et al. Inhibition of transcription factor NF - kappa B reduces matrix metalloproteinase - 1,- 3and - 9 production by vascular smooth muscle cells [ J ].Cardiovasc Res, 2001,50(3) :556 -565.
8[8]Bond M, Fabunmi RP, Baker AH, et al. Synergistic upregulation of metalloproteinase - 9 by growth factors and inflammatory cytokines: an absolute reauirement for transcription factor NFkappa B[J]. FEBS Lett, 1998, 435(1):29 -34.
